Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). (21st March 2020)
- Record Type:
- Journal Article
- Title:
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). (21st March 2020)
- Main Title:
- Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
- Authors:
- Guo, Li
Ren, Lili
Yang, Siyuan
Xiao, Meng
Chang, De
Yang, Fan
Dela Cruz, Charles S
Wang, Yingying
Wu, Chao
Xiao, Yan
Zhang, Lulu
Han, Lianlian
Dang, Shengyuan
Xu, Yan
Yang, Qi-Wen
Xu, Sheng-Yong
Zhu, Hua-Dong
Xu, Ying-Chun
Jin, Qi
Sharma, Lokesh
Wang, Linghang
Wang, Jianwei - Abstract:
- Abstract: Background: The emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. The current method of detection involves a quantitative polymerase chain reaction (qPCR)–based technique, which identifies the viral nucleic acids when present in sufficient quantity. False-negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19. Methods: The host humoral response against SARS-CoV-2, including IgA, IgM, and IgG response, was examined by using an ELISA-based assay on the recombinant viral nucleocapsid protein. 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but with typical manifestation). The diagnostic value of IgM was evaluated in this cohort. Results: The median duration of IgM and IgA antibody detection was 5 (IQR, 3–6) days, while IgG was detected 14 (IQR, 10–18) days after symptom onset, with a positive rate of 85.4%, 92.7%, and 77.9%, respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combining IgM ELISA assayAbstract: Background: The emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. The current method of detection involves a quantitative polymerase chain reaction (qPCR)–based technique, which identifies the viral nucleic acids when present in sufficient quantity. False-negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19. Methods: The host humoral response against SARS-CoV-2, including IgA, IgM, and IgG response, was examined by using an ELISA-based assay on the recombinant viral nucleocapsid protein. 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but with typical manifestation). The diagnostic value of IgM was evaluated in this cohort. Results: The median duration of IgM and IgA antibody detection was 5 (IQR, 3–6) days, while IgG was detected 14 (IQR, 10–18) days after symptom onset, with a positive rate of 85.4%, 92.7%, and 77.9%, respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combining IgM ELISA assay with PCR for each patient compared with a single qPCR test (51.9%). Conclusions: The humoral response to SARS-CoV-2 can aid in the diagnosis of COVID-19, including subclinical cases. Abstract : The time kinetics of humoral responses against the novel coronavirus (SARS-CoV-2) are characterized in patients with COVID-19 by nucleocapsid-based enzyme-linked immunosorbent assay. The antibody testing can aid in the diagnosis of COVID-19 when combined with quantitative polymerase chain reaction, including in subclinical cases. … (more)
- Is Part Of:
- Clinical infectious diseases. Volume 71:Number 15(2020)
- Journal:
- Clinical infectious diseases
- Issue:
- Volume 71:Number 15(2020)
- Issue Display:
- Volume 71, Issue 15 (2020)
- Year:
- 2020
- Volume:
- 71
- Issue:
- 15
- Issue Sort Value:
- 2020-0071-0015-0000
- Page Start:
- 778
- Page End:
- 785
- Publication Date:
- 2020-03-21
- Subjects:
- novel coronavirus -- COVID-19 -- antibody -- ELISA -- diagnosis
Communicable diseases -- Periodicals
616.905 - Journal URLs:
- http://cid.oxfordjournals.org ↗
http://ukcatalogue.oup.com/ ↗
http://www.journals.uchicago.edu/CID/journal ↗
http://www.jstor.org/journals/10584838.html ↗ - DOI:
- 10.1093/cid/ciaa310 ↗
- Languages:
- English
- ISSNs:
- 1058-4838
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.293860
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 27105.xml